Kawasaki Hastalığı
Özet
Kawasaki hastalığı (KH), en sık görülen pediatrik vaskülitlerden biridir. Çoğunlukla orta boy arterleri tutar. Genellikle 6 ay- 5 yaş arasında görülür. Kawasaki hastalığının akut fazı, hemodinamik dengesizlik ile ortaya çıkabilir. Başka bir sebeple açıklanamayan beş gün veya daha fazla süren ateş ile servikal lenfadenopati, konjonktivit, deri ve mukoza tutulumları ana bulgularıdır. Tedavi edilmediği takdirde koroner arter anormalliklerinin gelişme riskiyle ilişkilidir. Kardiyovasküler komplikasyonları önlemek için erken tedavi gereklidir.
Referanslar
Singh s, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis child. 2015;100(11):1084-8.
Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi. 1967;16(3):178-222.
Kasapçopur Ö, Arısoy N. Kawasaki hastalığı. Türk Pediatri Arşivi. 2008; 43:9-12.
Makino N, Nakamura Y, Yashiro M, et al. Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. Pediatr Int. 2019;61(4):397-403.
Singh s, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis child. 2015;100(11):1084-8.
Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from Mouse models. Nat Rev Rheumatol. 2020;16(7):391-405.
Takahashi K, Oharaseki T, Naoe S, et al. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int. 2005 Jun;47(3):305-10. doi: 10.1111/j.1442-200x.2005.02049.x. PMID: 15910456.
Biezeveld MH, van Mierlo G, Lutter R, et al. Sustained activation of neutrophils in the course of Kawasaki disease: an association with matrix metalloproteinases. Clin Exp Immunol. 2005 Jul;141(1):183-8. doi: 10.1111/j.1365-2249.2005.02829.x. PMID: 15958085; PMCID: PMC1809423.
Rife E, Gedalia A. Kawasaki Disease: an Update. Curr Rheumatol Rep. 2020;22(10):75.
Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from Mouse models. Nat Rev Rheumatol. 2020;16(7):391-405.
Li Q, Wang Y, Chen K, et al. The role of oxidized low-density lipoprotein in breaking peripheral Th17/Treg balance in patients with acute coronary syndrome. Biochem Biophys Res Commun. 2010 Apr 9;394(3):836-42. doi: 10.1016/j.bbrc.2010.03.090. Epub 2010 Mar 17. PMID: 20302843.
Shulman ST, Rowley AH. Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol. 2015 Aug;11(8):475-82. doi: 10.1038/nrrheum.2015.54. Epub 2015 Apr 28. PMID: 25907703.
Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from Mouse models. Nat Rev Rheumatol. 2020;16(7):391-405.
Kumrah R, Vignesh P, Rawat A, Singh S. Immunogenetics of Kawasaki disease. Clin Rev Allergy Immunol. 2020 Aug;59(1):122-139. doi: 10.1007/s12016-020-08783-9. PMID: 32200494.
Sharma K, Vignesh P, Srivastava P, et al. Epigenetics in Kawasaki Disease. Front Pediatr. 2021 Jun 25;9:673294. doi: 10.3389/fped.2021.673294. PMID: 34249810; PMCID: PMC8266996.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientic statement for health professionals from the American heart association. Circulation. 2017;135:e927-99.
Singh s, Jindal AK, Pilania RK. Diagnosis of Kawasaki disease. Int J Rheum Dis. 2018;21(1):36-44.
Pouletty M, Borocco C, Ouldali N, et al. Pediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa COVID-19): a multicentre cohort. Ann Rheum Dis. 2020;79:999-1006.
Koné-Paut I, Cimaz R. Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic. RMD Open. 2020;6(2):e001333.
Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow up study of 594 patients. circulation. 1996;94(6):1379-85.
de Graeff N, Groot N, Ozen s, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative. Rheumatology (Oxford). 2019;58(4):672-82.
Tang Y, Yan w, sun L, Xu Q, Ding Y, Lv H. coronary artery aneurysm regression after Kawasaki disease and associated risk factors: a 3-year follow-up study in East china. Clin Rheumatol. 2018;37(7):1945-51.
Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606–2612.
Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237–240.
Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131–137.
Rigante D, Andreozzi L, Fastiggi M, et al. critical Overview of the Risk scoring systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki syndrome. Int J Mol sci.2016;17(3):278.
Broderick C, Kobayashi S, Suto M, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease. Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014884. doi: 10.1002/14651858.CD014884.pub2. PMID: 36695415; PMCID: PMC9875364.
Fukazawa R, Kobayashi J, Ayusawa M, et al. Jcs/Jscs 2020 Guideline on Diagnosis and Management of cardiovascular sequelae in Kawasaki Disease. circ J. 2020;84(8):1348-407.
